Searchable abstracts of presentations at key conferences in endocrinology

ea0011p639 | Neuroendocrinology and behaviour | ECE2006

Anterior pituitary hormone dysfunction after traumatic brain injury: less common than previously thought?

Karavitaki N , Henderson-Slater JD , Wade DT , Wass JAH

Background: Traumatic brain injury (TBI) is a cause of hypopituitarism. Previous reports suggest complete or partial pituitary dysfunction in up to 40% of subjects.Aim: To investigate the presence of anterior pituitary hormone deficits in TBI patients tested at least 3 months after the injury.Patients and methods: The patients were recruited from those who have been assessed by the local Rehabilitation Centre over the last 5 years....

ea0011p760 | Steroids | ECE2006

Expression of oestrogen receptor related proteins beta occurs in multiple cell types within human endometrium during the normal menstrual cycle

Bombail V , Henderson T , Critchley HOD , Saunders PTK

Oestrogens are essential regulators of fertility in women. They induce changes in uterine cell function by binding to oestrogen receptors (ERs) two of which (ERα and ERß) have been identified. ERα and ERß share significant sequence homology with three other steroid receptor superfamily members that are known as oestrogen related receptors alpha (ERRα), beta (ERRß) and gamma (ERRγ). ERRs bind as monomers to the sequence TNAAGGTCA and as dimers...

ea0039oc6.7 | Oral Communications 6 | BSPED2015

Standard and modified release hydrocortisone formulations: cortisol levels and patient preference

Park J , Henderson T , Leyland H , Das U , Didi M , Ramakrishnan R , Peak M , Blair J

Background: Cortisol profiles during treatment with standard hydrocortisone (StdHC) formulations are unphysiological. Some patients, with low cortisol levels between doses, experience symptomatic hypocortisolaemia and may benefit from modified release hydrocortisone (MRHC). Plenadren is a MRHC licensed for once daily dosing in adults.We offered Plenadren to patients with symptomatic hypocortisolaemia, documented to occur at times of low cortisol levels, ...

ea0039ep18 | Bone | BSPED2015

Trends of use of bisphosphonates in children with secondary osteoporosis

Henderson S , Alhashem G , Shaikh G , Mason A , Ahmed S F , Wong S C

Aim: To review trends in bisphosphonate use in children with secondary osteoporosis attending a Tertiary Paediatric Endocrine Unit (2004–July 2015).Methods: Data were gathered from a combination of a clinical and pharmacy database. Results reported as median (range).Results: A total of 42 children (19M) commenced on bisphosphonates treatment over the 11-year period, median age 11.8 years (3.3–18.4). 19 were on pamidronate...

ea0058p081 | Diabetes | BSPED2018

Introduction of carbohydrate counting from diagnosis is associated with significant reduction in HbA1c in children with type 1 diabetes

Saranga Shyam S M , Henderson David , Thomas Vicky , Copley Sian , Hopper Neil W

Introduction: NICE NG18 recommends level 3 carbohydrate counting from diagnosis for CYP diagnosed with Type 1 Diabetes. Our unit introduced in-patient level 3 carb counting from day 1 in 2015 in response to an audit demonstrating sub-optimal control in the first year of treatment.Methods: We carried out a longitudinal study of HbA1c in paediatric patients during the first year of diagnosis in two time periods, before and after the introduction of carb co...

ea0005p150 | Endocrine Tumours and Neoplasia | BES2003

Expression of vascular endothelial growth factor and its receptors in human anterior pituitary adenomas

Adams I , Henderson R , Green V , Foy P , Macfarlane I , Atkin S

Vascular Endothelial Growth Factor (VEGF) is an important growth factor, simulating the process of angiogenesis which is required for tumour progression. It mainly acts through 2 receptors VEGF-R1 and VEGF-R2. Whilst the presence of VEGF has been shown in pituitary adenomas, no study has undertaken the quantification of the expression of VEGF121, VEGF165, VEGF-R1 and VEGF-R2, and whether their expression may correlate.METHODS. We have used the technique of quantitative RT-...

ea0086p70 | Metabolism, Obesity and Diabetes | SFEBES2022

Liver specific microparticles to improve islet transplantation outcomes in Type 1 diabetes

Walker Sophie , Lee I-ning , Gadd Victoria , Mellis David , Henderson John , Judge Amelia , Forbes Stuart , White Lisa , Forbes Shareen

Background: Islet transplant into the liver is a therapy for type 1 diabetes patients experiencing severe hypoglycaemia or impaired hypoglycaemic awareness. Widespread use is not currently considered due to the requirement for immunosuppression for the lifetime of the graft, and the attrition in graft function over the following 1-5 years. Following transplant into the liver, inflammation results in >60% islet loss, with few patients achieving insulin independence. The liv...